Selecting the right delivery and reimbursement model for Spravato has become one of the most strategic decisions a behavioral health or psychiatric practice will make in 2026. Reimbursement rates have shifted. Distributor contracts have tightened. Payors have increased documentation scrutiny. As a result, the financial gap between Buy & Bill and Specialty Pharmacy is wider than most practices realize.
This guide breaks down what is actually working inside clinics today, how the numbers perform in real-world settings, and where practices are inadvertently losing revenue without knowing it. As a leading Spravato Billing Services Company, Finnastra ensures clinics have the clarity needed to choose the right path and stay financially protected.
A Spravato program can generate a stable revenue stream, but only if the billing structure is aligned with updated reimbursement trends. Several shifts are influencing the landscape:
If you are planning to scale your Spravato program this year, you need a model that provides predictable cash flow and operational stability. That is especially true for practices adding TMS or ketamine services and want consistent reimbursement across modalities.
Many clinics still think Buy & Bill is risky because of upfront medication costs, yet the economics now favor clinics who manage the workflow correctly. Here is what we see across the practices we support:
Average Medication Cost (84 mg): $820 to $910
Average Payer Reimbursement (84 mg): $1,280 to $1,560
Average Margin per Treatment: $300 to $600
These margins hold as long as prior authorizations, benefit verifications, and coding accuracy are aligned with payor expectations.
When you work with a dedicated Spravato Billing Services Company like Finnastra, the entire cycle is managed end-to-end. That includes REMS-compliant documentation, buy-and-bill workflows, coding accuracy, and real-time AR monitoring. The result is fewer delays and fewer write-offs.
The real advantage of Buy & Bill: Guaranteed medication reimbursement + facility reimbursement + monitoring reimbursement. Practices retain control over the entire financial ecosystem.
If your clinic has steady patient volume or plans to grow, this model protects long-term revenue.
The Specialty Pharmacy model looks easier on the surface because the clinic does not pay for the drug upfront. But in 2026, more payors are reducing or denying facility and monitoring reimbursement when medication is dispensed outside the clinic.
Clinics that rely heavily on specialty pharmacy are often surprised when the expected operational “ease” turns into inconsistent scheduling and erratic revenue.
If you are running a high-volume program or treat multiple modalities, this model might actually limit your growth.
Below is a practical, economics-first breakdown using real clinic patterns:
Criteria |
Buy & Bill (2026) |
Specialty Pharmacy (2026) |
| Medication Margin | Yes | No |
| Schedule Reliability | High | Moderate |
| PA Control | High | Low |
| Cash Flow Predictability | Strong | Weak |
| Documentation Risk | Lower | Higher |
| Reimbursement Opportunities | Drug + Facility + Monitoring | Facility + Monitoring Only |
| Patient Continuity | Strong | Moderate |
If your practice is trying to decide which model fits your strategy, this table typically clarifies the path within minutes.
These questions often help leadership teams see the operational gaps that might not be obvious day-to-day.
Finnastra negotiates with all four major distributors to secure preferred pricing for clinics. That means lower drug acquisition costs, higher margins per treatment, and increased financial stability for your Spravato program.
This negotiation advantage is one of the biggest reasons clinics shift away from specialty pharmacy after reviewing their actual numbers with us.
Our Spravato Billing Services are designed to simplify the entire cycle. Coding, Prior Authorization, eligibility, claims submission, AR management, and documentation alignment are all handled by specialized teams who understand exactly how payors evaluate these claims.
As Spravato audit activity continues to grow in 2026, having a billing partner that protects both revenue and compliance is no longer optional.
Here’s the simplest summary:
Most established or growing practices see stronger margins and better operational stability from Buy & Bill. That trend is not expected to change over the next two years.
When you partner with Finnastra, you receive:
As a leading Spravato Billing Services Company, Finnastra ensures your practice has the clarity, structure, and operational expansion needed to run a profitable Spravato program from day one.
If you are evaluating Buy & Bill, considering a specialty pharmacy transition, or unsure which model is most profitable for your clinic, Finnastra can build a custom financial projection for your practice. Clinics typically uncover hidden reimbursement opportunities within the first call.
Visit our Spravato Billing Services page to explore how we support clinics nationwide:
